| 000 | 01799 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513200534.0 | ||
| 264 | 0 | _c20000120 | |
| 008 | 200001s 0 0 eng d | ||
| 022 | _a0889-2229 | ||
| 024 | 7 |
_a10.1089/088922299309766 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSpear, G T | |
| 245 | 0 | 0 |
_aAlteration of complement protein levels after antiretroviral therapy in HIV-infected persons. _h[electronic resource] |
| 260 |
_bAIDS research and human retroviruses _cDec 1999 |
||
| 300 |
_a1713-5 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Letter; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAnti-HIV Agents _xadministration & dosage |
| 650 | 0 | 4 | _aComplement Pathway, Classical |
| 650 | 0 | 4 |
_aComplement System Proteins _xanalysis |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 |
_aHIV Antibodies _ximmunology |
| 650 | 0 | 4 |
_aHIV Antigens _ximmunology |
| 650 | 0 | 4 |
_aHIV Infections _xblood |
| 650 | 0 | 4 |
_aHIV Protease Inhibitors _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLamivudine _xadministration & dosage |
| 650 | 0 | 4 |
_aReverse Transcriptase Inhibitors _xadministration & dosage |
| 650 | 0 | 4 |
_aRitonavir _xtherapeutic use |
| 650 | 0 | 4 | _aViral Load |
| 650 | 0 | 4 |
_aZidovudine _xtherapeutic use |
| 700 | 1 | _aOlinger, G | |
| 700 | 1 | _aSullivan, B L | |
| 700 | 1 | _aLanday, A L | |
| 700 | 1 | _aKessler, H | |
| 700 | 1 | _aConnick, E | |
| 700 | 1 | _aKuritzkes, D | |
| 700 | 1 | _aSt Clair, M | |
| 700 | 1 | _aSpritzler, J | |
| 700 | 1 | _aWu, H | |
| 700 | 1 | _aLederman, M M | |
| 773 | 0 |
_tAIDS research and human retroviruses _gvol. 15 _gno. 18 _gp. 1713-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1089/088922299309766 _zAvailable from publisher's website |
| 999 |
_c10562106 _d10562106 |
||